The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sushinskaya T.V.

P.A Herzen Moscow Research Oncology Institute — Branch of the National Medical Radiology Research Center

Li E.S.

AO «K+31»

Stuklov N.I.

P.A Herzen Moscow Research Oncology Institute — Branch of the National Medical Radiology Research Center;
People’s Friendship University of Russia

Anemia in oncology

Authors:

Sushinskaya T.V., Li E.S., Stuklov N.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2021;10(1): 64‑72

DOI: 10.17116/onkolog20211001164

Views: 3111

Downloaded: 100

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Sushinskaya TV, Li ES, Stuklov NI. Anemia in oncology. P.A. Herzen Journal of Oncology. 2021;10(1):64‑72. (In Russ.)
https://doi.org/10.17116/onkolog20211001164

МСФ на ЯМ
Close metadata

The paper is devoted to modern views on the problem of anemia, the most common pathological condition in cancer patients, which is caused by both the tumor process itself and the iatrogenic effect of special treatment.

OBJECTIVE

To present and analyze modern views on the etiology and pathogenesis of anemia in patients with malignant diseases. The paper sets forth current diagnostic approaches, gives optimal treatment regimens for anemia according to its severity, optimizes, and clarifies indications for the use of erythropoietin preparations in conjunction with blood transfusion, as well as for parenteral iron monotherapy. The authors consider that larger-scale randomized studies are now needed to compare the efficiency and safety of various treatment options for anemia in patients with malignant diseases, since anemia is an independent unfavorable prognostic factor associated with a more aggressive course and a more advanced stage of the malignant process, which requires compulsory consideration when deciding on the tactics of examination and treatment in each individual patient towards more radical approaches.

Keywords:

cancer
malignant neoplasms
anemia
iron deficiency anemia
anemia in cancer patients
etiology
pathogenesis
diagnosis
prevention
treatment
maintenance therapy
erythropoietin
monotherapy

Authors:

Sushinskaya T.V.

P.A Herzen Moscow Research Oncology Institute — Branch of the National Medical Radiology Research Center

Li E.S.

AO «K+31»

Stuklov N.I.

P.A Herzen Moscow Research Oncology Institute — Branch of the National Medical Radiology Research Center;
People’s Friendship University of Russia

Received:

27.09.2020

Accepted:

20.11.2020

List of references:

  1. Steegmann JL, Sánchez Torres JM, Colomer R, Vaz Á, López J, Jalón I, Provencio M, González-Martín A, Pérez M. Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. Clin Transl Oncol. 2013;15(6):477-483.  https://doi.org/10.1007/s12094-012-0953-5
  2. Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012;10(5):628-653.  https://doi.org/10.6004/jnccn.2012.0064.
  3. Van Belle S, Cocquyt V. Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol. 2003;47:1-11.  https://doi.org/1010.1016/s1040-8428(03)00093-3
  4. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE; American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008;26(1):132-49.  https://doi.org/10.1200/JCO.2007.14.3396
  5. Ludwig H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, Albrecht T, Abraham I.Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009;45(9):1603-1615. https://doi.org/10.1016/j.ejca.2009.02.003
  6. Shrivastava S, Mahantshetty U, Engineer R, Chopra S, Hawaldar R, Hande V, Kerkar RA, Maheshwari A, Shylasree TS, Ghosh J, Bajpai J, Gurram L, Gulia S, Gupta S; Gynecologic Disease Management Group. Cisplatin chemoradiotherapy vs radiotherapy in FIGO stage IIIB squamous cell carcinoma of the uterine cervix: a randomized clinical trial. JAMA Oncol. 2018;4(4):506-513.  https://doi.org/10.1001/jamaoncol.2017.5179
  7. Spivak JL. Iron and the anemia of chronic disease: vindication for the Non-essential role of iron supplementation. Oncology (Williston Park). 2011;25(5):421-423. 
  8. Adamson JW. The anemia of inflammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2008:159-165.  https://doi.org/10.1182/asheducation-2008.1.159
  9. Rodgers GM, Gilreath JA. The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy. Acta Haematol. 2019;142(1):13-20.  https://doi.org/10.1159/000496967
  10. Park S, Jung CW, Kim K, Kim SJ, Kim WS, Jang JH. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. Oncotarget. 2015;6(40):42803-42812. https://doi.org/10.18632/oncotarget.5658
  11. Lapin A. Soluble transferrin receptor: a new parameter for determining the status of iron. Laboratornaya meditsina. 2002;5:9-12. (In Russ).
  12. Wish JB. Assessing iron] status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(suppl 1):154-158.  https://doi.org/10.2215/CJN.01490506
  13. Zubrikhina GN, Blindar’ VN, Matveeva II. Differential diagnosis of anemic syndrome in absolute iron deficiency and functional iron deficiency in patients with chronic diseases (malignant neoplasms). Therapeutic archive=Terapevticheskii arkhiv. 2016;88(4):61-67. (In Russ.). https://doi.org/10.17116/terarkh201688461-67
  14. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008;13(suppl 3):21-26.  https://doi.org/10.1634/theoncologist.13-S3-21
  15. Blindar’ VN, Zubrikhina GN, Matveeva II. The main metabolites of ferrokinetics in the differential diagnosis of anemic syndrome. Russian Laboratory Clinical Diagnoctics=Klinicheskaya laboratornaya diagnostika. 2016;61(4):219-223. (In Russ). https://doi.org/10.18821/0869-2084-2016-61-4-219-223
  16. Wilson MJ, van Haaren M, Harlaar JJ, Park HC, Bonjer HJ, Jeekel J, Zwaginga JJ, Schipperus M. Long-term prognostic value of preoperative anemia in patients with colorectal cancer: a systematic review and meta-analysis. Surg Oncol. 2017;26(1):96-104.  https://doi.org/10.1016/j.suronc.2017.01.005
  17. Stuklov NI, Kozinets GI, Levakov SA, Ogurtsov PP. Anemia in gynecological and oncogynecological diseases. M.: MIA; 2013. (In Russ.).
  18. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004;9(suppl 5):31-40.  https://doi.org/10.1634/theoncologist.9-90005-31
  19. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem. 2008;8(7):790-797.  https://doi.org/10.2174/187152008785914798
  20. Wu HM, Jiang ZF, Ding PS, Shao LJ, Liu RY. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Sci Rep. 2015;5:12291. https://doi.org/10.1038/srep12291
  21. Vaupel P, Kelleher DK, Höckel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28(2, suppl 8):29-35.  https://doi.org/10.1016/S0093-7754(01)90210-6
  22. Vaupel P, Mayer A, Höckel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol. 2006;182(2):63-71.  https://doi.org/10.1007/s00066-006-1543-7
  23. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26(2):225-239.  https://doi.org/10.1007/s10555-007-9055-1
  24. Orlova RV, Gladkov OA, Zhukov NV, Kopp MV, Koroleva IA, Larionova VB, Moiseenko VM, Poddubnaya IV, Ptushkin VV. Practical guidelines for the treatment of anemia in malignant diseases neoplasms. Malignant tumours=Zlokachestvennye opukholi. 2019;9(3, suppl 2):458-465. (In Russ.). https://doi.org/10.18027/2224-5057-2019-9-3s2-558-565
  25. Murphy GH, Reeves BC, Rogers CA, Rizvi SIA, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007;116(22):2544-2552. https://doi.org/10.1016/j.jvs.2008.02.019
  26. Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A. Adverse blood transfusion outcomes: establishing causation. Transfus Med Rev. 2011;25(2):89-10.  https://doi.org/10.1016/j.tmrv.2010.11.001
  27. Baek JH, D’Agnillo F, Vallelian F, Pereira CP, Williams MC, Jia Y, Schaer DJ, Buehler PW.Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. J Clin Invest. 2012;122(4):1444-1458. https://doi.org/10.1172/JCI59770
  28. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377. https://doi.org/10.1001/archinte.168.21.2377
  29. Sushinskaya TV, Stuklov NI, Dobrokhotova YuE. Diagnostic significance of screening studies of the hemostatic system in patients with cervical cancer. Trombosis, Hemostasis and Rheology=Tromboz, gemostaz i reologiya. 2018;(2):99-104. (In Russ). https://doi.org/10.25555/THR.2018.1.0843
  30. Al-Refaie WF, Parsons HM, Markin A, Abrams J, Habermann EB. Blood transfusion and cancer surgery outcomes: a continued reason for concern. Surgery. 2012;152(3):344-354.  https://doi.org/10.1016/j.surg.2012.06.008
  31. Halabi WJ, Jafari MD, Nguyen VQ, Carmichael JC, Mills S, Pigazzi A, Stamos MJ. Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons National Surgical Quality Improvement Program analysis. Am J Surg. 2013;206(6):1024-1033. https://doi.org/10.1016/j.amjsurg.2013.10.001
  32. Amato A, Pescatori M. Perioperative blood transfusions and recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;(1):CD005033. https://doi.org/10.1002/14651858.CD005033.pub2
  33. Connor JP, O’Shea A, McCool K, Sampene E, Barroilhet LM. Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian cancer; potential impact of patient blood management on cancer outcomes. Gynecol Oncol. 2018;151(2):294-298.  https://doi.org/10.1016/j.ygyno.2018.08.040
  34. Bhat K, Sandler K, Duhachek-Muggy S, Alli C, Cheng F, Moatamed NA, Magyar CE, Du L, Li G, McCloskey S, Vlashi E, Pajonk F. Serum erythropoietin levels, breast cancer and breast cancer-initiating cells. Breast Cancer Res. 2019;21(1):17.  https://doi.org/10.1186/s13058-019-1100-9
  35. Bohlius Y, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3(8):1197-1210. https://doi.org/10.1182/bloodadvances.2018030387
  36. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, Lee J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998;100(1):79-89.  https://doi.org/10.1046/j.1365-2141.1998.00521.x
  37. Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. 2016;(2):CD009624. https://doi.org/10.1002/14651858.CD009624.pub2
  38. Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, Kim JH, Kim JW. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105(1):199-204.  https://doi.org/10.1093/annonc/mds338
  39. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116(3):522-525.  https://doi.org/10.1016/j.ygyno.2009.12.004
  40. Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdelelah H. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study. Drug Des Devel Ther. 2013;7:939-934.  https://doi.org/10.2147/DDDT.S45674
  41. Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131(3):679-682.  https://doi.org/10.1016/j.ygyno.2013.09.028
  42. Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475-482.  https://doi.org/10.1093/annonc/mds338
  43. Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, Birgegård G. Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Med Oncol. 2014;31(12):302.  https://doi.org/10.1007/s12032-014-0302-3
  44. Birgegard G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. A randomized noninferority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the PROFOUND Trial. Pharmacotherapy. 2016;36(4):402-414.  https://doi.org/10.1002/phar.1729
  45. Vadhan-Raj S, Dahl NV, Bernard K, Li Z, Strauss WE. Efficacy and safety of IV ferumoxytol for iron deficiency anemia in patients with cancer. J Blood Med. 2017;8:199-209.  https://doi.org/10.2147/jbm.s138474
  46. Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM Jr, Novotny PJ, Loprinzi CL. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011;29(1):97-105.  https://doi.org/10.1200/JCO.2010.30.3644
  47. Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, Maisano R. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Support Care Cancer. 2017;25(9):2779-2786. https://doi.org/10.1007/s00520-017-3690-z
  48. Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(suppl 4):96-110.  https://doi.org/10.1093/annonc/mdx758
  49. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Society of Hematology and the American Society of Clinical Oncology Practice Guideline Update Committee. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045-4059. https://doi.org/10.1200/JCO.2009.23.5622
  50. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004;76(1):7-78.  https://doi.org/10.1002/ajh.20056
  51. Gilreath JA, Stenehjem DD, Rodgers GM. Total dose iron dextran infusion in cancer patients: is it SaFe2+? J Natl Compr Canc Netw. 2012;10(5):669-676.  https://doi.org/10.6004/jnccn.2012.066
  52. Jaspers A, Baron F, Maertens J, De Prijck B, Schots R, Bonnet C, Hafraoui K, Willems É, Servais S, Fillet G, Beguin Y. Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. Am J Hematol. 2015;90(7):133-134.  https://doi.org/10.1002/ajh.24013

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.